Silver Book Fact

Projections of Significant Heart Valve Disease — Diagnosed & Undiagnosed — in the 65+ U.K. Population

D'Arcy J, Coffeey S, Loudon M, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. European Heart Journal. 2016; 34(47). https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehw229

Reference

Title
Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study
Publication
European Heart Journal
Publication Date
2016
Authors
D'Arcy J, Coffeey S, Loudon M, et al
Volume & Issue
Volume 34, Issue 47
URL
Read Full Resource

Categories

  • Cost of Disease
  • Future Economic Burden

Related Facts

  • 2016 prevalence of aortic valve disease in America
    In 2016, as many as 5.8 million U.S. adults had aortic valve disease (AVD). Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007  
  • Survival rates for SAS patients without treatment
     
  • Low detection rates for AS
    Prevalence estimates for AS are likely low. A U.K. population screening found previously undetected HVD in 1 in 2 adults ages 65+.  
  • Lifespan of Medicare patients with sSAS who do not undergo treatment
    Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.  
  • 1 and 6-month mortality rates without treatment for sSAS
    Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).